LDA1
56 evidence topics · 4 sources
Objective
Registered purpose
Published objective
“A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present LSD study was designed to evaluate previous findings applying current research methodology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Objective of the qualitative follow-up
“Participants of this study were included in a prospective follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study identifiers, dates, and status
| Item | Registry record |
|---|---|
| Other study ID | “LDA1” |
| Phase | “Phase 2” |
| Study start | “2008-02” |
| Primary completion (actual) | “2011-04-14” |
| Study completion (actual) | “2012-09” |
| First posted (estimated) | “2009-06-15” |
| Results first posted | “2021-12-08” |
| Last update posted | “2023-07-12” |
Site: one private practice in Switzerland
Study design
Official title and registered design
| Design element | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
Active placebo control and open-label crossover
“This phase 2 double-blind, active placebo-controlled, randomized clinical trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two months after the second experimental session, a follow-up evaluation was completed, and the treatment period was finished by breaking the blind for each individual. The participants who received the active placebo could cross over to an identical but open-label treatment with 200 μg of LSD. A long-term follow-up evaluation was conducted 12 months after the last experimental session with LSD in either the blinded portion of the study or the open-label crossover.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ethics and regulatory approvals
“was approved by the Ethics Committee of the Canton of Aargau, Swissmedic, the Swiss Federal Office for Public Health (Bundesamt fuer Gesundheit [Swiss Ministry of Health]), and the US Food and Drug Administration (Investigational New Drug no. 101,825) and was conducted in accordance with Good Clinical Practices.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Funding and sponsor
“This study was funded in part by Schweizerische Aerztegesellschaft für Psycholytische Therapie (Swiss Medical Society for Psycholytic Therapy) and Multidisciplinary Association for Psychedelic Studies. Rick Doblin (president) and Berra Yazar-Klosinski are employees of the main sponsor MAPS. Peter Gasser is president of SAEPT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria
Exclusion criteria
Eligibility as published: STAI threshold and exclusions
“Individuals with current alcohol or drug dependence (except caffeine or nicotine); primary psychotic, bipolar I affective, or dissociative disorders; and neurocognitive impairment and women who were pregnant or nursing were excluded from this study. All participants reported a score of greater than 40 on either the state or the trait scale of the Spielberger State-Trait Anxiety Inventory” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recruitment
Treatment
Registered treatment arms
Study drug: LSD free base capsules
“LSD was supplied as free base by Lipomed (Arlesheim, Switzerland). Capsules consisting of 200 μg (experimental dose) and 20 μg of LSD (active placebo) were prepared by Bichsel Laboratories (Interlaken, Switzerland).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Capsules were of identical size, color, and shape and were bottled in sequentially numbered containers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Experimental sessions and dose selection
“The primary intervention consisted of two full-day experimental sessions scheduled 2 to 3 weeks apart with a male/female co-therapist team, embedded within an ongoing process of drug-free psychotherapy sessions for preparatory and integrative purposes. The participants were randomly assigned to the experimental dose groups, receiving either an oral dose of 200 μg of LSD (n = 8) or an active placebo of 20 μg of LSD (n = 4). The experimental dose was a moderate amount expected to produce the full spectrum of a typical LSD experience, without fully dissolving normal ego structures. The 20-μg dose of LSD was chosen as an active placebo to produce short-lived, mild, and detectable LSD effects that would not substantially facilitate a therapeutic process.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Session setting, duration, and psychotherapy
“Two preparatory psychotherapy sessions served to discuss the participant’s history, social situation, personality, health, mind-set, and emotional situation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other than going to the bathroom, the participants remained in the treatment room for the entire 8-hour experimental session and overnight with an attendant nearby.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The therapeutic session ended after 8 hours, when the acute effects had subsided, followed by a brief review of the day’s experiences. After each experimental session, three drug-free psychotherapy sessions lasting 60 to 90 minutes took place, during which the participant’s experiences were reviewed for integration and deepening the therapeutic process.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concomitant medications and restrictions
“The participants were required to taper off of antidepressants and antianxiety medications, to avoid alcohol and recreational drugs for 24 hours before, and to abstain from driving for 24 hours after the experimental sessions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the study, two participants (both experimental dose) received concomitant selective serotonin reuptake inhibitor (SSRI) treatment for depression and tapered off of these medications five half-lives before each experimental session because SSRIs may attenuate the effects of the serotonergically active experimental drug” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three participants received benzodiazepines (two experimental dose and one active placebo) as needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using State-Trait anxiety inventory score as the primary endpoint
STAI as the primary outcome measure
“The STAI Form X, a widely used self-report instrument for assessing state and trait anxiety in adults, served as the primary outcome measure of anxiety symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcome measures were completed at baseline, 1 week after experimental sessions, 2-month follow-up, and 12-month follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered primary outcome and scale description
Secondary outcome measures
“Secondary outcome measures included the European Cancer Quality of Life Questionnaire 30-item version 1.0” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the SCL-90-R” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and the Hospital Anxiety and Depression Scale” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After each experimental session, the State of Consciousness Questionnaire was completed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Screened, enrolled, and randomized
“Of 70 participants who were evaluated for eligibility by telephone or e-mail, 20 were further screened in person, and 12 were enrolled in this study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The participants received either 200 μg of LSD (n = 8) or 20 μg of LSD with an open-label crossover to 200 μg of LSD after the initial blinded treatment was unmasked (n = 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analyzed: 8 and 3 participants
“One active placebo participant was excluded from analysis after completing all study procedures because of a correction in the diagnosis of the qualifying disease state, which no longer satisfied the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Values are mean ± SEM of changes from baseline in eight subjects in the LSD group and three subjects in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sample size basis
“As a pilot study, this study had limited sample size, which reduced precision in effect size estimates and significance testing. The sample size selected was sufficient for a study primarily focused on safety and feasibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants assessed at 12 months in the qualitative follow-up
Description of analysis sets
Statistical methods and multiplicity
“Repeated-measures analysis of variance (ANOVA) was used to test for significant changes in anxiety from baseline to subsequent posttreatment measurements. STAI trait and STAI state were analyzed in separate ANOVAs. To account for multiplicity, the alpha level indicating significance was adjusted to 0.025 (two tailed). Effect sizes were estimated using Cohen’s d techniques. Results of the 12-month follow-up were compared with those of the 2-month follow-up with paired t-tests. Secondary outcome measures conducted for exploratory purposes were not used for significance testing to reduce multiplicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Handling of missing data and exclusion from analysis
“We were unable to obtain results for two subjects (one experimental dose, one active placebo) from the assessment conducted 1 week after the second experimental session because of intervening cancer treatments. To avoid substantially reducing the sample size because of missing data, the assessment 1 week after the second experimental session was dropped for all subjects from analysis of outcomes. One active placebo participant was excluded from analysis after completing all study procedures because of a correction in the diagnosis of the qualifying disease state, which no longer satisfied the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Registry participant flow
Baseline characteristics
Registry baseline characteristics
| Characteristic | Full dose LSD (200 mcg) | Active placebo LSD (20 mcg) | Total |
|---|---|---|---|
| Participants | “8” | “3” | “11” |
| Age, years, mean (SD) | “49.6(8.4)” | “57.4(9.9)” | “51.7(9.1)” |
| Female | “3” | “1” | “4” |
| Male | “5” | “2” | “7” |
| History of suicidal tendencies: none | “8” | “1” | “9” |
| History of suicidal tendencies: mild | “0” | “2” | “2” |
| Metastatic breast carcinoma | “3” | “1” | “4” |
| Metastatic gastric carcinoma | “2” | “0” | “2” |
| Plasmocytoma | “1” | “0” | “1” |
| Non-Hodgkin's Lymphoma | “0” | “1” | “1” |
| Celiac Disease | “0” | “1” | “1” |
| Parkinson's Disease | “1” | “0” | “1” |
| Bechterew's Disease | “1” | “0” | “1” |
Baseline STAI scores (registry primary outcome at baseline, visit 4)
| STAI subscale, mean (SD) | Full dose LSD (200 mcg), n = 8 | Active placebo LSD (20 mcg), n = 3 |
|---|---|---|
| STAI-state | “53.1(4.7)” | “47.7(7.7)” |
| STAI-trait | “53.2(4.3)” | “43.3(7.0)” |
Race and ethnicity not collected
Diagnoses and prior LSD experience
“Eleven of the 12 subjects had no prior experience with LSD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“half of the subjects were diagnosed with generalized anxiety disorder (GAD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline comparability of STAI scores
“No significant difference was found (p = 0.261) between group mean scores at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant difference was found between the groups at baseline (p = 0.563).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Primary endpoint: STAI at 2 months after the second session (registry)
| STAI subscale, mean (SD) | Full dose LSD (200 mcg), n = 8 | Active placebo LSD (20 mcg), n = 3 |
|---|---|---|
| STAI-state | “41.5(3.2)” | “51.7(5.3)” |
| STAI-trait | “45.2(3.7)” | “49.0(6.1)” |
Primary endpoint: published analysis
“At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trait anxiety
“The visit × group interaction testing for differences between the groups produced p = 0.033 (F = 4.151, df = 2,18), and observed statistical power was 65.6%, with results trending toward statistical significance. Comparing trait anxiety at baseline with 2-month follow-up yielded an effect size of 1.1. However, only three of eight experimental dose subjects dropped lower than the threshold value of 40 after the intervention. In contrast, all active placebo subjects experienced increases in trait anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
State anxiety
“The visit × group interaction testing for differences between the groups produced p = 0.021 (F = 4.846, df = 2,18), and observed statistical power was 72.7%. Even controlling for multiplicity, the reductions in state anxiety were statistically significant 2 months after two experimental sessions of LSD-assisted psychotherapy. Comparing state anxiety at baseline with 2-month follow-up yielded an effect size of 1.2. However, only three of eight experimental dose subjects dropped lower than the diagnostic cutoff of 40 after the intervention. In contrast, two active placebo subjects experienced increases in state anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Durability at 12 months
“Comparison of 2-month and 12-month follow-up results in the subjects who received 200 μg of LSD in either the blinded sessions or the open-label crossover indicate that the benefits were sustained over time. The mean difference varied only by 0.667 between these assessments, and no significant difference was found with p = 0.825 (two tailed).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparison of 2-month and 12-month follow-up results in the subjects who received 200 μg of LSD in either the blinded sessions or the open-label crossover indicates that the benefits were sustained over time. The mean difference varied only by 1.00 between these assessments, and no significant difference was found with p = 0.531 (two tailed).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospital Anxiety and Depression Scale
“The experimental dose group mean (SD) anxiety scores decreased from 11.7 (3.4) to 8.1 (3.2) after two sessions, whereas the active placebo group anxiety scores decreased only from 11.3 (2.1) to 10.7 (3.0). The active placebo subjects who continued to the crossover experienced an even greater decline lower than the diagnostic cutoff for anxiety to 7.0 (2.6). All subjects who received the experimental dose were lower than the diagnostic cutoff at the 12-month follow-up, with a mean (SD) of 7.6 (4.5). The depression results also mirrored the anxiety results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Quality of life: EORTC-QLQ global health score
“Global health scores from the EORTC-QLQ increased from a mean (SD) of 37.4 (10.0) at baseline to 50.0 (14.9) after treatment with two sessions of 200 μg of LSD, whereas mean scores decreased from 44.3 (12.7) to 36.0 (12.8) in the active placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
General psychopathology: SCL-90-R Global Severity Index
“Global Severity Index (GSI) scores from the SCL-90-R decreased from a mean (SD) T-score of 69.6 (6.7) at baseline to 60.2 (7.2) in the experimental dose group whereas increasing from 66.0 (15.1) to 67.7 (10.2) in the active placebo group. The active placebo group experienced an improvement comparable with the full-dose group after receiving the experimental dose in the open-label crossover, with mean (SD) T-scores dropping to 57.3 (15.0).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participant-reported changes at 12 months (qualitative content analysis)
Safety results
Severe and related adverse events as published
“Neither the experimental dose (200 μg of LSD) nor the active placebo (20 μg of LSD) produced any drug-related severe adverse events, that is, no panic reaction, no suicidal crisis or psychotic state, and no medical or psychiatric emergencies requiring hospitalization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The experimental dose subjects experienced more types of AEs (n = 18) than the active placebo subjects (n = 8). In general, AEs were reported more frequently and with increased intensity in the experimental dose sessions. Interestingly, fewer reports of anxiety were received during experimental sessions with 200 μg (22.7%) than with active placebo (50%), and the mean intensity of anxiety was comparable between the groups. However, the subjects reported experiencing mild-to-moderate emotional distress similarly in experimental dose sessions (36.4%) and active placebo sessions (33.3%). Most AEs resolved when drug effects diminished. Only six reports of mild related AEs (illusions, feeling cold or abnormal, and some emotional distress) persisted until the next day. No flashback phenomena or other prolonged effects were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vital signs and rescue medication
“LSD did not significantly alter blood pressure or heart rate” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three participants received pain medication during the study, only one of which was required as rescue medication for a treatment-emergent AE. Acetaminophen was required for this participant for a moderate headache the day after an experimental dose session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry adverse events: mortality, serious, and selected other adverse events
| Adverse event (affected / at risk) | Full dose LSD (200 mcg), stage 1 | Active placebo LSD (20 mcg), stage 1 | Full dose LSD (200 mcg), stage 2 |
|---|---|---|---|
| All-cause mortality | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Serious adverse events, total | “1/8 (12.50%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Serious: metastatic esophageal cancer | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Serious: pyelonephritis | “0/8 (0.00%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Other adverse events, total | “8/8 (100.00%)” | “4/4 (100.00%)” | “3/3 (100.00%)” |
| Feeling cold | “6/8 (75.00%)” | “0/4 (0.00%)” | “1/3 (33.33%)” |
| Illusions | “6/8 (75.00%)” | “1/4 (25.00%)” | “2/3 (66.67%)” |
| Emotional distress | “5/8 (62.50%)” | “1/4 (25.00%)” | “0/3 (0.00%)” |
| Feeling abnormal | “5/8 (62.50%)” | “2/4 (50.00%)” | “1/3 (33.33%)” |
| Time perception altered | “4/8 (50.00%)” | “0/4 (0.00%)” | “2/3 (66.67%)” |
| Mydriasis | “3/8 (37.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
| Anxiety | “2/8 (25.00%)” | “2/4 (50.00%)” | “1/3 (33.33%)” |
| Impaired gait | “2/8 (25.00%)” | “0/4 (0.00%)” | “2/3 (66.67%)” |
| Hallucination | “1/8 (12.50%)” | “0/4 (0.00%)” | “0/3 (0.00%)” |
Study limitations
Summary
LDA1 was a phase 2 pilot trial at one private practice in Solothurn, Switzerland, with the Multidisciplinary Association for Psychedelic Studies (MAPS) named as main sponsor; MAPS co-funded the trial, and the funding statement names two MAPS employees. Twelve participants with anxiety associated with life-threatening diseases were randomized to LSD 200 μg (8 participants) or an active placebo of LSD 20 μg (4 participants); one active placebo participant was excluded from analysis after a correction of the qualifying diagnosis, leaving 8 and 3 participants. The authors state that the sample size was sufficient for a study primarily focused on safety and feasibility and that the limited sample reduced precision in effect size estimates and significance testing.
With the alpha level adjusted to 0.025 for multiplicity, the reduction in state anxiety (p = 0.021) met the threshold and the reduction in trait anxiety (p = 0.033) did not. Only three of eight participants in the 200 μg group fell below the threshold of 40 on each subscale. The assessment 1 week after the second session was dropped for all participants because results were missing for two participants, and secondary outcomes were not tested for significance. The 12-month comparisons included participants who received 200 μg in the open-label crossover and had no concurrent control, and the qualitative follow-up tested 10 participants.
Blinding was not maintained: for all 24 blinded sessions, all participants correctly guessed the dose, and the authors state that the 20-μg dose was too low to achieve uncertainty about the dose. Half of the participants received a SCID diagnosis of generalized anxiety disorder, and the authors state that this does not mean the participants had the conventional pattern of psychopathology usually associated with GAD, because the SCID items do not differentiate GAD from a reaction to a life-threatening disease. The registry lists the illnesses as metastatic breast carcinoma (4 participants), metastatic gastric carcinoma (2), and plasmocytoma, non-Hodgkin's lymphoma, celiac disease, Parkinson's disease, and Bechterew's disease (1 each); mean age was 51.7 years, 7 of 11 participants were male, and race and ethnicity were not collected. The authors state that the course of the somatic illness may affect psychological parameters independent of the intervention, and that the EORTC-QLQ focused on physical aspects and was insufficient for evaluating long-term psychological changes.
The intervention combined LSD capsules with two preparatory psychotherapy sessions, three drug-free integrative psychotherapy sessions after each experimental session, and a male and female co-therapist team, with 8-hour experimental sessions and an overnight stay. The publication reports no drug-related severe adverse events; the registry reports serious adverse events of metastatic esophageal cancer (1 of 8) and pyelonephritis (1 of 4) and all-cause mortality of 1 of 8 in the 200 μg group. The registry and the publication differ on two details: the registry requires a score of at least 40 on each part of the STAI and spaces sessions two to four weeks apart, while the publication states that participants scored greater than 40 on either the state or the trait scale and that sessions were 2 to 3 weeks apart.
Limitations stated by the authors: sample size, blinding, and dose
“As a pilot study, this study had limited sample size, which reduced precision in effect size estimates and significance testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The imperfect blinding also limits the validity of the results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although using a slightly higher LSD dose in the comparator group can increase blinding, it can also increase efficacy of the comparator, compromising the estimates of effect size. Given the safety of the moderate experimental dose, results might have been improved with a larger dose of 250 μg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding assessment
“For all 24 blinded sessions, all participants correctly guessed the dose of LSD that was administered, and both therapists guessed incorrectly in one active placebo session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This indicates that the 20-μg dose was too low to achieve successful uncertainty about the dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations stated by the authors: somatic illness and quality of life measure
“Other limitations exist in treating participants with grave somatic diseases because the course of the somatic illness (e.g., worsening or improving) may substantially impact psychological parameters independent of the therapeutic intervention and contribute to missing data. The quality of life questionnaire (EORTC-QLQ), which was chosen as a secondary outcome measure, focuses extensively on physical aspects and was insufficient for evaluating long-term psychological changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Applicability of the GAD diagnosis
“Neither the SCID’s five items about GAD nor criterion E for GAD in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, differentiates between anxiety typically seen with GAD and a reaction to a life-threatening disease (and its consequences). Therefore, even though the SCID generates a diagnosis of GAD, this does not mean that the subjects had the conventional pattern of psychopathology usually associated with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of sessions
“Most of the participants stated a preference for more than two LSD sessions and a longer treatment period. The results demonstrated a decrease in STAI scores most prominently after the second LSD session, suggesting that at least two LSD sessions are needed to demonstrate these effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote